






  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="robots" content="noindex,nofollow"/>
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil - Tabular View - ClinicalTrials.gov</title>
    <link href="/ct2/show/record/NCT02822235" rel="canonical"/>
  
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish-vertical.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/base.css?v=b4" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/print.css" media="print" />
  <link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct.css" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct-oldIE.css" type="text/css" />
  <![endif]-->
  	

     <!--[if lte IE 7]>
           <link href="/ct2/html/ct3/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
    <![endif]-->

<link href="/ct2/html/ct3/css/trial-record.css?v=b4" rel="stylesheet" type="text/css" />
<link href="/ct2/html/ct3/css/ct2Header.css" rel="stylesheet" type="text/css" />


	<script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.min.js?v=1.12.4"></script><noscript></noscript>
	    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/superclick.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.cookie.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/images/frame/ct.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/js/ctmenu.js?v=b4"></script><noscript></noscript>

    <script type="text/javascript" src="/ct2/html/images/foresee/foresee-trigger.js"></script><noscript></noscript>
<script type="text/javascript">
    $(window).load(function(){
        loadCTCommon();
        });
</script>
 


  <script type="text/javascript">
    ncbi_pingWithImage=true;
    __ncbi_stat_url="//www.ncbi.nlm.nih.gov/stat";        
  </script>
  
  <meta name="ncbi_sid" content="861650e698601876_927f1SID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_record"/>
  <meta name="ncbi_pcid" content="NCT02822235"/>
  <meta name="ncbi_ctreqid" content="RRe02WwY"/>
  <meta name="ncbi_ctsessid" content="SRe01hyp"/>
  <meta name="ncbi_ctipid" content="IzOkI5NS"/>
  <meta name="ncbi_cthost" content="wp2"/>
</head>

<body class="js one-column"> 
<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>

<script type="text/javascript">
	var RetractableBannerStateProperty = 'CT_NewsBannerState';
	
	ToggleBanner = function()
    {
        var theAccordion = $('#retractableBanner'); 
       	if (theAccordion.css("display") == "none") {
        		$('#showMore').css('visibility', 'hidden');
        	} else {
         		$('#showMore').css('visibility', 'visible');
        	}
        theAccordion.slideToggle({
            duration: 'fast',
            start: function(){
				            	if (typeof FuncReAlign !== 'undefined') {
            		$( "table.fixedHeader-floating" ).hide();
            	}
			},
            done: function(){
            	if (theAccordion.css("display") == "none") {
            		rememberRetractableBannerState('hide');
            	} else {
            		rememberRetractableBannerState('show');
            	}
            	if (typeof FuncReAlign !== 'undefined') {
                	FuncReAlign();  
            		$( "table.fixedHeader-floating" ).show();
            	}
            }
		});
    };
	    
	var rememberRetractableBannerState = function(newState) {
		try {
			sessionStorage.setItem(RetractableBannerStateProperty, newState);
		} catch (e) {}
	};

	$(window).ready(function(){
		try {
			var retractableBannerState = sessionStorage.getItem(RetractableBannerStateProperty);
					    if (retractableBannerState === null  || retractableBannerState === 'show') {
				ToggleBanner();
			}
		} catch (e) {};
	});
</script><noscript></noscript>
<div class="w3-container w3-center" style="padding:1.5ex 0.125in 0;background:#205493;color:white">
	<div style="font-weight:bold;">This site became the new ClinicalTrials.gov on June 19th. <a href="https://www.nlm.nih.gov/pubs/techbull/mj17/mj17_clinicaltrials_improve_usability.html" style="margin-left:1em;color:white;border-bottom-color:white;">Learn more.</a>
		<div id="showMore" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show more <img src="/ct2/html/ct3/images/show-more.png" style="width:17px;"></div>
	</div>
	<div id="retractableBanner" style="margin-top:1ex;display:none;">We will be updating this site in phases. This allows us to move faster and to deliver better services.
		<div id="showLess" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show less <img src="/ct2/html/ct3/images/show-less.png" style="width:17px;"></div>
	</div>
</div>
<div id="wrapper" style="padding-top:0;">  <div id="longAlert" class="w3-hide-small" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study.  <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>
<div id="shortAlert" class="w3-hide-medium w3-hide-large" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Talk with a trusted healthcare professional before volunteering for a study. <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>

  
	<div id="header" style="float:left;"> <a href="/ct2/home" style="border-style:none;box-shadow:none;"><img src='/ct2/html/ct3/images/ct.gov-logo.png' alt='ClinicalTrials.gov' style='max-width:100%;' /></a><br />
    	<div id="tagline">A service of the U.S. National Institutes of Health</div>
  	</div>
					<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/ct3/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
					</ul>
				</div>
    		</div>
  		</div>		

	  	<div id="savedStudies" style="float:right;padding:4px 8px;"> 		  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
		  	<button class="savedStudiesEnabled" id="open-cart-link" type="button" 
		  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
		  		title="Show previously saved studies.">Saved Studies</button>
		  	</div>
			<button class="savedStudiesDisabled" id="cart-disabled" type="button" disabled
				title="There are no saved studies to show. You can save studies to visit later from the search results page">Saved Studies (0)</button>
		</div>

		<div style="clear:right;text-align:right;padding-top:1ex;padding-right:8px;font-size:small;">
			<a href="https://survey.foreseeresults.com/survey/display?cid=WyHFr2m0PoaGCBUsi00QIQ==&sid=link-ct" target="_blank">Give us feedback</a></div>
		<script type="text/javascript" src="/ct2/html/ct3/js/cart.js?v=b4"></script><noscript></noscript>
  	
<div id="global-nav" class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
			<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
	</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div> 

<div id="utilities">
     
</div>
<div id="breadcrumb">
	<ul class="horz-list">
		<li><a href="/ct2/home">Home</a></li>
				<li class="last">Study Record Detail</li>
	</ul>
</div>


<div id="main-content">


        	<h1 class="solo_record">Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil</h1>
	<div id="trial-info-1" class="floater-50">

     


      
        <div  class="not-recruiting-status" >
      This study is ongoing, but not recruiting participants.
          </div>
        
        
      
        




                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> Takeda </div>



                              <div class="info-title">Information provided by (Responsible Party):</div>
                <div class="info-text">Takeda</div>
              

            </div>
               <div id="trial-info-2" class="floater-50">
                <div class="info-title">ClinicalTrials.gov Identifier:</div>
                <div class="identifier">NCT02822235</div>
                <div class="info-date">First received: June 30, 2016</div>
                <div class="info-date">Last updated:  March 9, 2017</div>
                <div class="info-date">Last verified:  March 2017 </div>
                <div class="info-date"> <a href="/ct2/archive/NCT02822235"
          title="Historical versions of study NCT02822235 on ClinicalTrials.gov Archive Site - opens in new window"
          onclick="openNewWindow('/ct2/archive/NCT02822235'); return false;">History of Changes</a> </div>
            </div>



<div id="tabs">
        <ul id="tab-links">
			<li id="full-text" ><a href="/ct2/show/study/NCT02822235"  >Full Text View</a></li>
			<li id="tabular"     class="current"> Tabular View       </li>
			<li id="results"   ><a href="/ct2/show/results/NCT02822235">No Study Results Posted</a></li>
			<li id="disclaimer"><a href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
        </ul>
</div>  <div style="background-color:#f6f6f6;margin-top:3.5ex;padding-bottom:3.5ex;"> </div>




<!-- field list -->
<div class="indent1">
 
  <table class="w3-table data_table tableStyle">
    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Tracking Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">First Received Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">June 30, 2016</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Last Updated Date </th>
            <td class="body3 rowBody">March 9, 2017</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Start Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">October 2016</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Estimated Primary Completion Date </th>
            <td class="body3 rowBody">January 2018 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;June 30, 2016)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Percentage of Participants With Active Crohn&apos;s Disease (CD) at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Participants With Active Ulcerative Colitis (UC) at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]</li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><i style="color:#777777">Same as current</i></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Change History </th>
            <td class="body3 rowBody"><a href="/ct2/archive/NCT02822235" onclick="openNewWindow('/ct2/archive/NCT02822235'); return false;">Complete list of historical versions of study NCT02822235 on ClinicalTrials.gov Archive Site</a></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;February 21, 2017)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Distribution of Gender by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">IBD types include Ulcerative Colitis and Crohn&apos;s Disease.</div></li>
<li style="margin:1ex 0.5ex">Distribution of Age by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">IBD types include Ulcerative Colitis and Crohn&apos;s Disease.</div></li>
<li style="margin:1ex 0.5ex">Distribution of Smoking Habits, Professional Status, Family History, Educational Level, Subject Income by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">IBD types include Ulcerative Colitis and Crohn&apos;s Disease.</div></li>
<li style="margin:1ex 0.5ex">Distribution of Clinical Variables by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">IBD types include Ulcerative Colitis and Crohn&apos;s Disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants by Type of Therapies for IBD [&nbsp;Time&nbsp;Frame:&nbsp;Within the previous 3 years including Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Therapies for IBD include aminosalicylates, steroids, immunomodulators, immunossupressors, biologics, antibiotics, probiotics and surgeries.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants With Biologic-experience [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants who received biologic therapy will be reported.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants who Have not Responded Previously to Biologic Therapies [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Participants With IBD Treatment Introduced at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]</li>
<li style="margin:1ex 0.5ex">Distribution of Socio-Demographic Variables in Participants With Moderate to Severe Activity of CD(Harvey Bradshaw Index[HBI] &#8805;8 or Crohn&apos;s Disease Activity Index[CDAI] &#8805;220 points) Versus Participants With Light or no Activity(HBI &lt;8 or CDAI&lt;220 points) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Socio-demographic variables include age, gender and professional status (employed, unemployed, retired, student, other).</div></li>
<li style="margin:1ex 0.5ex">Distribution of Clinical Variables in Participants with Moderate to Severe Activity of CD (HBI &#8805;8 or CDAI &#8805;220 points) Versus Participants With Light or no Activity (HBI &lt;8 or CDAI &lt;220 points) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical variables include family history of IBD, smoking habits, medical history comorbidities, disease presentation [location, behavior, extraintestinal manifestations (EIM)], steroid behavior (dependent or refractory), colonoscopy in the previous year suggestive of inadequate control of activity (yes/no), calprotectin levels in the previous year suggestive of inadequate control of activity (i.e., calprotectin &gt;200 &#181;g/g) (yes/no) and eligibility for 12-month prospective follow up (yes/no).</div></li>
<li style="margin:1ex 0.5ex">Distribution of Treatment Related Variables in Participants With Moderate to Severe Activity of CD (HBI &#8805;8 or CDAI &#8805;220 points) Versus Participants With Light or no Activity (HBI &lt;8 or CDAI &lt;220 points) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Treatment variables include previous treatments or regimens (aminosalicylates, steroids, immunomodulators, immunossupressors, biologics, probiotics, antibiotics); reason for discontinuation and previous surgeries for IBD.</div></li>
<li style="margin:1ex 0.5ex">Distribution of Socio-Demographic Variables in Participants With Moderate to Severe Activity of UC (Partial Mayo Score &#8805;5) Versus Participants With Light or no Activity (Partial Mayo &lt;5) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Socio-demographic variables include age, gender and professional status (employed, unemployed, retired, student, other).</div></li>
<li style="margin:1ex 0.5ex">Distribution of Clinical Variables in Participants with Moderate to Severe Activity of UC (Partial Mayo Score &#8805;5) Versus Participants With Light or no Activity (Partial Mayo &lt;5) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical variables include family history of IBD, smoking habits, medical history comorbidities, disease presentation [location, behavior, extraintestinal manifestations (EIM)], steroid behavior (dependent or refractory), colonoscopy in the previous year suggestive of inadequate control of activity (yes/no), calprotectin levels in the previous year suggestive of inadequate control of activity (i.e., calprotectin &gt;200 &#181;g/g) (yes/no) and eligibility for 12-month prospective follow up (yes/no).</div></li>
<li style="margin:1ex 0.5ex">Distribution of Treatment Related Variables in Participants with Moderate to Severe Activity of UC (Partial Mayo Score &#8805;5) Versus Participants With Light or no Activity (Partial Mayo &lt;5) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Treatment variables include previous treatments or regimens (aminosalicylates, steroids, immunomodulators, immunossupressors, biologics, probiotics, antibiotics); start date; end date, dose, reason for discontinuation, treatment started at Day 1 and previous surgeries for IBD.</div></li>
<li style="margin:1ex 0.5ex">HBI Score After 12 Months Among Participants who had Moderately to Severely Active CD at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1 and Month 12&nbsp;]<div class="indent2" style="margin-top:1ex;">The HBI is used in the assessment and quantification of symptoms and the present level of disease activity of participants with CD. It is a validated clinical index for CD, including the 5 categories of: general well-being, abdominal pain, number of liquid stools, abdominal mass and complications. The score ranges from 0 to 25 with higher scores indicating higher disease activity. The scores were classified as follows: less than 5 is remission, 5 to 7 is mild, 8 to 16 is moderate, and greater than 16 is severe.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score After 12 Months Among Participants who had Moderately to Severely Active CD at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1 and Month 12&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI evaluates severity of signs and symptoms of CD. Information will be collected on number of liquid stools, intensity of abdominal pain, general well-being, presence of comorbid conditions, use of medications for diarrhea, physical examination, and laboratory, yielding 8 items that are combined with data from a 7-day diary to obtain total CDAI score. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease, values &#8805;220 indicates moderate to severe disease, and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Partial Mayo Score After 12 Months Among Participants who had Moderately to Severely Active UC at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1 and Month 12&nbsp;]<div class="indent2" style="margin-top:1ex;">The partial Mayo score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician&apos;s Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants who Change IBD Treatment After 12 Months Among Participants who had Moderately to Severely Active CD [&nbsp;Time&nbsp;Frame:&nbsp;Month 12&nbsp;]</li>
<li style="margin:1ex 0.5ex">Mean Score of 5-dimensional EuroQoL Measure (EQ-5D) by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">EuroQoL questionnaire (EQ-5D) considers five attributes of quality of life evaluation, i.e mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has five possible levels, 1-no problems, 2 slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems, thus defining a total of 3125 possible health states, each one referred to in terms of a 5 digit code. EQ-5D also include an additional visual analogic scale (EQ-VAS), which ranges from 0, worst imaginable health state, to 100, best imaginable health state.</div></li>
<li style="margin:1ex 0.5ex">Mean Score of Different Components of SF-36 by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">The Short Form-36 (SF-36) evaluates 8 health dimensions: physical functioning, bodily pain, role physical (limitations due to physical problems), role emotional (limitations due to personal or emotional problems), mental health, social functioning, vitality, and general health perceptions. Based on these 8 scales, two weighted scores are generated: the physical component summary (PCS) and the mental component summary (MCS) score. Scores range between 0 and 100, with higher scores indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Mean Total Score of Inflammatory Bowel Disease Questionnaire (IBDQ) and by Domain (Bowel Symptoms, Systemic Symptoms, Emotional Function and Social Function) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item questionnaire that measures 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. Within dimensions, each question presents seven possible answers/points. Each domain score is the sum of 8 responses each ranging from 1 to 7, where 1 indicates worst function and 7 the best. The sub-score ranges from 8 to 56; a higher score indicating a better quality of life. Hence, the total score ranges from 32 to 224, with higher scores representing better quality of life. The IBDQ is not validated for patients with ostomies and therefore should not be applied for these patients.</div></li>
<li style="margin:1ex 0.5ex">Mean of Participants&apos; Total Percentage of Work Impairment (Work Productivity and Activity Impairment [WPAI] Questionnaire) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">The Work Productivity and Activity Impairment questionnaire (WPAI) assesses the impact of IBD on work productivity and daily activities during the previous 7 days. The WPAI questions are: 1) if currently employed, 2) hours missed due to disease, 3) hours missed other reasons, 4) hours actually worked, 5) degree disease affected productivity while working, 6) degree disease affected regular activities. WPAI generates four component scores: percentage of work time missed (absenteeism); percentage of impairment while working (presentisms); percentage of overall work impairment (absenteeism and presentisms combined); and percentage of activity impairment. Unemployed participants only answer questions related to employment status and activity impairment. Scores for WPAI range from 0% (no impairment) to 100% (total loss of work productivity/activity).</div></li>
<li style="margin:1ex 0.5ex">Mean Work Time Missed From WPAI Questionnaire [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Mean work time missed due to disease from WPAI questionnaire will be reported. The WPAI assesses the impact of IBD on work productivity and daily activities during the previous 7 days. The WPAI questions are: 1) if currently employed, 2) hours missed due to disease, 3) hours missed other reasons, 4) hours actually worked, 5) degree disease affected productivity while working, 6) degree disease affected regular activities. WPAI generates four component scores: percentage of work time missed (absenteeism); percentage of impairment while working (presentisms); percentage of overall work impairment (absenteeism and presentisms combined); and percentage of activity impairment. Unemployed participants only answer questions related to employment status and activity impairment. Scores for WPAI range from 0% (no impairment) to 100% (total loss of work productivity/activity).</div></li>
<li style="margin:1ex 0.5ex">Mean Impairment While Working From WPAI Questionnaire [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Mean impairment while working due to disease from WPAI questionnaire will be reported. The WPAI assesses the impact of IBD on work productivity and daily activities during the previous 7 days. The WPAI questions are: 1) if currently employed, 2) hours missed due to disease, 3) hours missed other reasons, 4) hours actually worked, 5) degree disease affected productivity while working, 6) degree disease affected regular activities. WPAI generates four component scores: percentage of work time missed (absenteeism); percentage of impairment while working (presentisms); percentage of overall work impairment (absenteeism and presentisms combined); and percentage of activity impairment. Unemployed participants only answer questions related to employment status and activity impairment. Scores for WPAI range from 0% (no impairment) to 100% (total loss of work productivity/activity).</div></li>
<li style="margin:1ex 0.5ex">Mean Total Activity Impairment From WPAI Questionnaire [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Mean total activity impairment due to disease from WPAI questionnaire will be reported. The Work Productivity and Activity Impairment questionnaire (WPAI) assesses the impact of IBD on work productivity and daily activities during the previous 7 days. The WPAI questions are: 1) if currently employed, 2) hours missed due to disease, 3) hours missed other reasons, 4) hours actually worked, 5) degree disease affected productivity while working, 6) degree disease affected regular activities. WPAI generates four component scores: percentage of work time missed (absenteeism); percentage of impairment while working (presentisms); percentage of overall work impairment (absenteeism and presentisms combined); and percentage of activity impairment. Unemployed participants only answer questions related to employment status and activity impairment. Scores for WPAI range from 0% (no impairment) to 100% (total loss of work productivity/activity).</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants who Used Healthcare Resources [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Healthcare resources used in the previous 3 years including imaging and laboratory testing, surgeries, hospitalizations, consultations and adverse events.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;June 30, 2016)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Distribution of Gender by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">IBD types include Ulcerative Colitis and Crohn&apos;s Disease.</div></li>
<li style="margin:1ex 0.5ex">Distribution of Age by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">IBD types include Ulcerative Colitis and Crohn&apos;s Disease.</div></li>
<li style="margin:1ex 0.5ex">Distribution of Smoking Habits and Professional Status by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">IBD types include Ulcerative Colitis and Crohn&apos;s Disease.</div></li>
<li style="margin:1ex 0.5ex">Distribution of Clinical Variables by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">IBD types include Ulcerative Colitis and Crohn&apos;s Disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants by Type of Therapies for IBD [&nbsp;Time&nbsp;Frame:&nbsp;Within the previous 3 years including Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Therapies for IBD include aminosalicylates, steroids, immunomodulators, immunossupressors, biologics, antibiotics, probiotics and surgeries.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants With Biologic-experience [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants who received biologic therapy will be reported.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants who Have not Responded Previously to Biologic Therapies [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Participants With IBD Treatment Introduced at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]</li>
<li style="margin:1ex 0.5ex">Distribution of Socio-Demographic Variables in Participants With Moderate to Severe Activity of CD(Harvey Bradshaw Index[HBI] &#8805;8 or Crohn&apos;s Disease Activity Index[CDAI] &#8805;220 points) Versus Participants With Light or no Activity(HBI &lt;8 or CDAI&lt;220 points) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Socio-demographic variables include age, gender and professional status (employed, unemployed, retired, student, other).</div></li>
<li style="margin:1ex 0.5ex">Distribution of Clinical Variables in Participants with Moderate to Severe Activity of CD (HBI &#8805;8 or CDAI &#8805;220 points) Versus Participants With Light or no Activity (HBI &lt;8 or CDAI &lt;220 points) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical variables include family history of IBD, smoking habits, medical history comorbidities, disease presentation [location, behavior, extraintestinal manifestations (EIM)], steroid behavior (dependent or refractory), colonoscopy in the previous year suggestive of inadequate control of activity (yes/no), calprotectin levels in the previous year suggestive of inadequate control of activity (i.e., calprotectin &gt;200 &#181;g/g) (yes/no) and eligibility for 12-month prospective follow up (yes/no).</div></li>
<li style="margin:1ex 0.5ex">Distribution of Treatment Related Variables in Participants With Moderate to Severe Activity of CD (HBI &#8805;8 or CDAI &#8805;220 points) Versus Participants With Light or no Activity (HBI &lt;8 or CDAI &lt;220 points) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Treatment variables include previous treatments or regimens (aminosalicylates, steroids, immunomodulators, immunossupressors, biologics, probiotics, antibiotics); reason for discontinuation and previous surgeries for IBD.</div></li>
<li style="margin:1ex 0.5ex">Distribution of Socio-Demographic Variables in Participants With Moderate to Severe Activity of UC (Partial Mayo Score &#8805;5) Versus Participants With Light or no Activity (Partial Mayo &lt;5) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Socio-demographic variables include age, gender and professional status (employed, unemployed, retired, student, other).</div></li>
<li style="margin:1ex 0.5ex">Distribution of Clinical Variables in Participants with Moderate to Severe Activity of UC (Partial Mayo Score &#8805;5) Versus Participants With Light or no Activity (Partial Mayo &lt;5) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical variables include family history of IBD, smoking habits, medical history comorbidities, disease presentation [location, behavior, extraintestinal manifestations (EIM)], steroid behavior (dependent or refractory), colonoscopy in the previous year suggestive of inadequate control of activity (yes/no), calprotectin levels in the previous year suggestive of inadequate control of activity (i.e., calprotectin &gt;200 &#181;g/g) (yes/no) and eligibility for 12-month prospective follow up (yes/no).</div></li>
<li style="margin:1ex 0.5ex">Distribution of Treatment Related Variables in Participants with Moderate to Severe Activity of UC (Partial Mayo Score &#8805;5) Versus Participants With Light or no Activity (Partial Mayo &lt;5) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Treatment variables include previous treatments or regimens (aminosalicylates, steroids, immunomodulators, immunossupressors, biologics, probiotics, antibiotics); start date; end date, dose, reason for discontinuation, treatment started at Day 1 and previous surgeries for IBD.</div></li>
<li style="margin:1ex 0.5ex">HBI Score After 12 Months Among Participants who had Moderately to Severely Active CD at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1 and Month 12&nbsp;]<div class="indent2" style="margin-top:1ex;">The HBI is used in the assessment and quantification of symptoms and the present level of disease activity of participants with CD. It is a validated clinical index for CD, including the 5 categories of: general well-being, abdominal pain, number of liquid stools, abdominal mass and complications. The score ranges from 0 to 25 with higher scores indicating higher disease activity. The scores were classified as follows: less than 5 is remission, 5 to 7 is mild, 8 to 16 is moderate, and greater than 16 is severe.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score After 12 Months Among Participants who had Moderately to Severely Active CD at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1 and Month 12&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI evaluates severity of signs and symptoms of CD. Information will be collected on number of liquid stools, intensity of abdominal pain, general well-being, presence of comorbid conditions, use of medications for diarrhea, physical examination, and laboratory, yielding 8 items that are combined with data from a 7-day diary to obtain total CDAI score. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease, values &#8805;220 indicates moderate to severe disease, and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Partial Mayo Score After 12 Months Among Participants who had Moderately to Severely Active UC at Day 1 [&nbsp;Time&nbsp;Frame:&nbsp;Day 1 and Month 12&nbsp;]<div class="indent2" style="margin-top:1ex;">The partial Mayo score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician&apos;s Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants who Change IBD Treatment After 12 Months Among Participants who had Moderately to Severely Active CD [&nbsp;Time&nbsp;Frame:&nbsp;Month 12&nbsp;]</li>
<li style="margin:1ex 0.5ex">Mean Score of 5-dimensional EuroQoL Measure (EQ-5D) by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">EuroQoL questionnaire (EQ-5D) considers five attributes of quality of life evaluation, i.e mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has three possible levels, i.e 1-no problems, 2-some or moderate problems, or 3-major problems, thus defining 243 possible health states, to which has been added &quot;unconscious&quot; and &quot;dead&quot;, for a total of 245. The scores are combined to form a single index utility value between 0.0 and 1.0. The EQ-5D index has an upper limit of 1 that indicates full health (indicated by &quot;no problem&quot; in all domains), whereas 0 represents death.</div></li>
<li style="margin:1ex 0.5ex">Mean Score of Different Components of SF-36 by IBD Type [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">The Short Form-36 (SF-36) evaluates 8 health dimensions: physical functioning, bodily pain, role physical (limitations due to physical problems), role emotional (limitations due to personal or emotional problems), mental health, social functioning, vitality, and general health perceptions. Based on these 8 scales, two weighted scores are generated: the physical component summary (PCS) and the mental component summary (MCS) score. Scores range between 0 and 100, with higher scores indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Mean Total Score of Inflammatory Bowel Disease Questionnaire (IBDQ) and by Domain (Bowel Symptoms, Systemic Symptoms, Emotional Function and Social Function) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item questionnaire that measures 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. Within dimensions, each question presents seven possible answers/points. Each domain score is the sum of 8 responses each ranging from 1 to 7, where 1 indicates worst function and 7 the best. The sub-score ranges from 8 to 56; a higher score indicating a better quality of life. Hence, the total score ranges from 32 to 224, with higher scores representing better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Mean of Participants&apos; Total Percentage of Work Impairment (Work Productivity and Activity Impairment [WPAI] Questionnaire) [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">The Work Productivity and Activity Impairment questionnaire (WPAI) assesses the impact of IBD on work productivity and daily activities during the previous 7 days. The WPAI questions are: 1) if currently employed, 2) hours missed due to disease, 3) hours missed other reasons, 4) hours actually worked, 5) degree disease affected productivity while working, 6) degree disease affected regular activities. WPAI generates four component scores: percentage of work time missed (absenteeism); percentage of impairment while working (presentisms); percentage of overall work impairment (absenteeism and presentisms combined); and percentage of activity impairment. Unemployed participants only answer questions related to employment status and activity impairment. Scores for WPAI range from 0% (no impairment) to 100% (total loss of work productivity/activity).</div></li>
<li style="margin:1ex 0.5ex">Mean Work Time Missed From WPAI Questionnaire [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Mean work time missed due to disease from WPAI questionnaire will be reported. The WPAI assesses the impact of IBD on work productivity and daily activities during the previous 7 days. The WPAI questions are: 1) if currently employed, 2) hours missed due to disease, 3) hours missed other reasons, 4) hours actually worked, 5) degree disease affected productivity while working, 6) degree disease affected regular activities. WPAI generates four component scores: percentage of work time missed (absenteeism); percentage of impairment while working (presentisms); percentage of overall work impairment (absenteeism and presentisms combined); and percentage of activity impairment. Unemployed participants only answer questions related to employment status and activity impairment. Scores for WPAI range from 0% (no impairment) to 100% (total loss of work productivity/activity).</div></li>
<li style="margin:1ex 0.5ex">Mean Impairment While Working From WPAI Questionnaire [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Mean impairment while working due to disease from WPAI questionnaire will be reported. The WPAI assesses the impact of IBD on work productivity and daily activities during the previous 7 days. The WPAI questions are: 1) if currently employed, 2) hours missed due to disease, 3) hours missed other reasons, 4) hours actually worked, 5) degree disease affected productivity while working, 6) degree disease affected regular activities. WPAI generates four component scores: percentage of work time missed (absenteeism); percentage of impairment while working (presentisms); percentage of overall work impairment (absenteeism and presentisms combined); and percentage of activity impairment. Unemployed participants only answer questions related to employment status and activity impairment. Scores for WPAI range from 0% (no impairment) to 100% (total loss of work productivity/activity).</div></li>
<li style="margin:1ex 0.5ex">Mean Total Activity Impairment From WPAI Questionnaire [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Mean total activity impairment due to disease from WPAI questionnaire will be reported. The Work Productivity and Activity Impairment questionnaire (WPAI) assesses the impact of IBD on work productivity and daily activities during the previous 7 days. The WPAI questions are: 1) if currently employed, 2) hours missed due to disease, 3) hours missed other reasons, 4) hours actually worked, 5) degree disease affected productivity while working, 6) degree disease affected regular activities. WPAI generates four component scores: percentage of work time missed (absenteeism); percentage of impairment while working (presentisms); percentage of overall work impairment (absenteeism and presentisms combined); and percentage of activity impairment. Unemployed participants only answer questions related to employment status and activity impairment. Scores for WPAI range from 0% (no impairment) to 100% (total loss of work productivity/activity).</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants who Used Healthcare Resources [&nbsp;Time&nbsp;Frame:&nbsp;Day 1&nbsp;]<div class="indent2" style="margin-top:1ex;">Healthcare resources used in the previous 3 years including imaging and laboratory testing, surgeries, hospitalizations, consultations and adverse events.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Descriptive Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Official Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Real-world Data of Moderate to Severe Inflammatory Bowel Disease in Brazil: a Non-interventional, Multicenter Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life (RISE BR)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Summary </th>
            <td class="body3 rowBody">The purpose of this study is to gather information regarding the population with moderate to severe inflammatory bowel disease (IBD), the burden of the disease, and understand their treatment patterns, particularly on the use of available biologic therapies.</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Detailed Description </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">This is a non-interventional study to determine the rate of control of disease activity in moderate to severe IBD participants.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The study will enroll approximately 400 patients. This multicenter trial will be conducted in Brazil. Retrospective data of previous IBD treatments (drug, dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years will be collected. Prospective data will be collected for a period of 12 months in participants with active disease. UC participants, with no or light disease activity at Day 1 will not continue to 12-month follow up. CD participants, with no or light disease activity at Day 1 but with colonoscopy or calprotectin levels (i.e, calprotectin &gt;200 ug/g) in the previous year suggestive of inadequate control of activity will progress to 12-month follow up.</p></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Type&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Observational</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Design&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Observational Model: Cohort<br/>Time Perspective: Prospective</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Target Follow-Up Duration </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Biospecimen </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Sampling Method </th>
            <td class="body3 rowBody">Non-Probability Sample</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Population </th>
            <td class="body3 rowBody">Adult participants diagnosed with moderate to severe Crohn's Disease (CD) or Ulcerative Colitis (UC) will be observed.</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Condition&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Inflammatory Bowel Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Intervention&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Other: No Intervention</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Groups/Cohorts </th>
            <td class="body3 rowBody">Cohort 1
<div class="indent2" style="margin-top:0.5ex">Retrospective data including previous inflammatory bowel disease (IBD) treatments (drug, dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years will be collected from participants with UC or CD. Prospective data will be collected for a period of 12 months after Day 1 in participants with active IBD (UC or CD) and CD participants with no or light disease activity at Day 1 but with colonoscopy or calprotectin levels (i.e, calprotectin &gt;200 &#181;g/g) in the previous year suggestive of inadequate control of activity.</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Other: No Intervention</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Publications * </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        * &nbsp; Includes publications given by the data provider as well as publications
        identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
      </td>
    </tr>

    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Recruitment Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Recruitment Status&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Active, not recruiting</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Estimated Enrollment&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">400</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Estimated Completion Date </th>
            <td class="body3 rowBody">January 2018</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Estimated Primary Completion Date </th>
            <td class="body3 rowBody">January 2018 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Eligibility Criteria&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Male or female.</li>
    <li style="margin-top:0.7ex;">18 years or older (at the time of diagnosis of moderate to severe UC or CD).</li>
    <li style="margin-top:0.7ex;">Diagnosis of moderate to severe CD or UC for at least 6 months prior to Day 1 appointment according the clinical or endoscopic criteria.</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Has provided the written informed consent.</p>
      <p style="margin-top:0ex; margin-bottom:1ex;">For the prospective period, eligible participants should present at least one of the following criteria that will only be applied at Day 1:</p>
    </li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">For CD participants:</p>
      <ul style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">Harvey Bradshaw Index (HBI) &#8805;8 or</li>
        <li style="margin-top:0.7ex;">Crohn's Disease Activity Index (CDAI) &#8805;220 or</li>
      </ul>
      <p style="margin-top:0ex; margin-bottom:1ex;">Considering that for CD participants, the disease activity may not be clearly documented only with clinical data, some objective criteria may be considered as entry criteria for the 12-month prospective period:</p>
      <ul style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">Colonoscopy in the previous year suggestive of inadequate control of activity or,</li>
        <li style="margin-top:0.7ex;">Calprotectin levels in the previous year suggestive of inadequate control of activity (i.e, calprotectin &gt;200 &#181;g/g).</li>
      </ul>
    </li>
    <li style="margin-top:0.7ex;">For UC: partial Mayo Score &#8805;5. Note : Patients with colostomy and prospective period: Although clinical scales defined above are impacted by colostomy these patients will not be excluded from the protocol to ensure the assessment of different clinical presentations of the IBD. In addition, patients with colostomy must follow the same criteria as above to be eligible to the prospective phase.</li>
  </ol>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Indeterminate or not classified colitis.</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Current or previous participation in interventional clinical trial (within the last 3 years).</p>
      <p style="margin-top:0ex; margin-bottom:1ex;">In addition, for the 12-month prospective period, participants will be excluded if:</p>
    </li>
    <li style="margin-top:0.7ex;">Presenting mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.</li>
    <li style="margin-top:0.7ex;">Hospitalized participants at Day 1.</li>
    <li style="margin-top:0.7ex;">Current off label treatment with Vedolizumab.</li>
  </ol>
  <p style="margin-top:0ex; margin-bottom:1ex;">Study Discontinuation Criteria</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">It will be considered a premature termination the situation in which the subject discontinues the participation, i.e. they are withdrawn from the study before completing the 12 months of follow up period (365 days &#177; 14 days from Day 1), due to any of the reasons listed below:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Withdrawal of consent: subjects who for any reason withdraw the free and informed consent;</li>
    <li style="margin-top:0.7ex;">Lost to follow-up (no return of the subject on the expected date of visit - drop-out from the protocol);</li>
    <li style="margin-top:0.7ex;">Death;</li>
    <li style="margin-top:0.7ex;">Study termination;</li>
    <li style="margin-top:0.7ex;">Any situation that places the subject within one of the exclusion criteria.</li>
  </ol>
  <p style="margin-top:0ex; margin-bottom:1ex;">Note: Patients who are eligible for the prospective period, it means, with active disease at Day 1 but who during the 12 months period presents disease remission and/or no activity disease condition, are allowed to continue the participation in the study.</p></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Sex/Gender </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Sexes Eligible for Study:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">All</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Ages </th>
            <td class="body3 rowBody">18 Years and older &nbsp; (Adult, Senior)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Accepts Healthy Volunteers </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Contacts&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><i style="color:#777777">Contact information is only displayed when the study is recruiting subjects</i></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Listed Location Countries&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Brazil</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Removed Location Countries </th>
            <td class="body3"> &nbsp; </td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Administrative Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">NCT Number&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">NCT02822235</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Other Study ID Numbers&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Vedolizumab-4008<br> U1111-1178-66445 ( Registry Identifier: WHO )</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Has Data Monitoring Committee </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">U.S. FDA-regulated Product </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">IPD Sharing Statement </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Responsible Party </th>
            <td class="body3 rowBody">Takeda</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Sponsor&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Takeda</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Collaborators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Investigators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Study Director:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">Medical Director Clinical Science</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">Takeda</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">PRS Account </th>
            <td class="body3 rowBody">Takeda</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Verification Date </th>
            <td class="body3 rowBody">March 2017</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        <sup style="color:blue"> ICMJE </sup>&nbsp; &nbsp; Data element required by the
        <a href="http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html">
        International Committee of Medical Journal Editors</a> and the
        <a href="http://www.who.int/ictrp/network/trds/en/index.html">World Health Organization ICTRP</a>
      </td>
    </tr>

  </table>
</div>


<div id="to-top"><a href="#wrapper">To Top</a></div>

	<div style="clear:both;"></div>
</div> 

      <div id="for-footer">
        <ul class="horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

<div id="footer-menu">
    <ul class="horz-list">
		<li><a href="/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a     href="/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a         href="/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a       href="/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="/ct2/about-site/disclaimer" style="white-space:nowrap">Disclaimer</a></li>
		<li><a        href="https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT02822235" style="white-space:nowrap" onclick="openNewWindow('https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT02822235'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li                  ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li                  ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li                  ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li                  ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li                  ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

    <script type="text/javascript" src="/ct2/html/ct3/js/instrumentNCBIBaseJS.min.js"></script><noscript></noscript>

</body>
</html>
